The estimated Net Worth of Brian Goff is at least $22.4 Millón dollars as of 8 August 2024. Mr. Goff owns over 22,691 units of Alexion Pharmaceuticals stock worth over $16,455,780 and over the last 7 years he sold ALXN stock worth over $387,010. In addition, he makes $5,547,010 as Executive Vice President y Chief Commercial and Global Operations Officer at Alexion Pharmaceuticals.
Brian has made over 9 trades of the Alexion Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 22,691 units of ALXN stock worth $4,154,268 on 8 August 2024.
The largest trade he's ever made was exercising 25,528 units of Alexion Pharmaceuticals stock on 28 June 2023 worth over $4,673,666. On average, Brian trades about 6,031 units every 95 days since 2017. As of 8 August 2024 he still owns at least 89,883 units of Alexion Pharmaceuticals stock.
You can see the complete history of Mr. Goff stock trades at the bottom of the page.
Brian M. Goff serves as Executive Vice President, Chief Commercial and Global Operations Officer of the Company. He is Executive Vice President, Chief Commercial and Global Operations Officer of Alexion. Mr. Goff leads the global commercial and operations teams, which includes responsibility for country operations in each of Alexion’s affiliates in North America, EMEA, Japan, Asia Pacific, and Latin America. Mr. Goff is a proven global biopharmaceutical executive with a 25-year track record of consistently delivering sustainable growth through multiple business cycles. He has deep expertise in commercial operations across multiple therapeutic areas, as well as broad expertise managing global cross-functional teams, including R&D, Medical Affairs, Manufacturing and Quality with a number of industry-leading biopharmaceutical companies. Prior to joining Alexion in June 2017, Mr. Goff was Chief Operating Officer and a Member of the Board of Directors of Neurovance Inc. from December 2016 until its acquisition by Otsuka Pharmaceuticals in March 2017. Prior to joining Neurovance, Mr. Goff served as Baxalta’s Executive Vice President & President — Hematology Division from January 2015 to July 2016. He previously served with Baxter Healthcare Corporation as Global Hemophilia Franchise Head from June 2012 to December 2014. Earlier in his career, Mr. Goff held positions of increasing responsibility in sales and marketing roles with Novartis Pharmaceuticals, and the pharmaceutical division of Johnson & Johnson. Mr. Goff has an MBA from the Wharton School at the University of Pennsylvania and a Bachelor of Arts from Skidmore College.
As the Executive Vice President y Chief Commercial and Global Operations Officer of Alexion Pharmaceuticals, the total compensation of Brian Goff at Alexion Pharmaceuticals is $5,547,010. There are 2 executives at Alexion Pharmaceuticals getting paid more, with Ludwig Hantson having the highest compensation of $18,948,000.
Brian Goff is 50, he's been the Executive Vice President y Chief Commercial and Global Operations Officer of Alexion Pharmaceuticals since 2019. There are 14 older and 4 younger executives at Alexion Pharmaceuticals. The oldest executive at Alexion Pharmaceuticals Inc. is John Mollen, 69, who is the Independent Director.
Brian's mailing address filed with the SEC is C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 21 years, insiders at Alexion Pharmaceuticals have traded over $451,742,532 worth of Alexion Pharmaceuticals stock and bought 2,576,434 units worth $277,855,180 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Leonard Bell y Paul A Friedman. On average, Alexion Pharmaceuticals executives and independent directors trade stock every 9 days with the average trade being worth of $3,460,578. The most recent stock trade was executed by Daniel Bazarko on 17 December 2020, trading 24,066 units of ALXN stock currently worth $2,816,685.
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Alexion Pharmaceuticals executives and other stock owners filed with the SEC include: